

IMMUNALL SCIENCE INC.

Condensed Interim Financial Statements

For the three months ended March 31, 2015

(amounts in Canadian Dollars)

(unaudited)

IMMUNALL SCIENCE INC.

CONDENSED INTERIM FINANCIAL STATEMENTS

For the three months ended March 31, 2015

(amounts in Canadian Dollars)

(Unaudited)

NOTICE TO THE READERS OF THE CONDENSED INTERIM FINANCIAL STATEMENTS

The financial statements of Immunall Science Inc. comprising the accompanying condensed balance sheet as at March 31, 2015 and the condensed statement of loss and comprehensive loss, statement of changes in shareholders equity and statement of cash flows for the three month period then ended are the responsibility of the company's management.

UNAUDITED INTERIM FINANCIAL STATEMENTS

These financial statements have not been reviewed on behalf of the shareholders by the independent external auditors Collins Barrow Calgary LLP, chartered accountants. The interim financial statements have been prepared by management and include the selection of appropriate accounting principles, judgements and estimates necessary to prepare these financial statements in accordance with International Financial Reporting Standards.

IMMUNALL SCIENCE INC.

Index to Interim Financial Statements

March 31, 2015

(amounts in Canadian Dollars)

(unaudited)

	Page
MANAGEMENTS RESPONSIBILITY FOR UNAUDITED INTERIM FINANCIAL STATEMENTS	1
FINANCIAL STATEMENTS	
Interim Statements of Financial Position	2
Interim Statements of Loss and Comprehensive Loss	3
Interim Statements of Changes in Equity	4
Interim Statements of Cash Flows	5
Notes to the Interim Financial Statements	6-14

IMMUNALL SCIENCE INC.

March 31, 2015

MANAGEMENT'S RESPONSIBILITY FOR UNAUDITED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited interim financial statements of Immunall Science Inc. (the "Company") are the responsibility of management.

The unaudited interim financial statements have been prepared by management, on behalf of the Board of Directors, in accordance with the accounting policies disclosed in the notes to the unaudited interim financial statements. Where necessary, management has made informed judgments and estimates in accounting for transactions which were not complete at the financial position date. In the opinion of management, the unaudited interim financial statements have been prepared within acceptable limits of materiality and are in accordance with International Accounting Standard 34 Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards appropriate in the circumstances.

Management has established processes, which are in place to provide it sufficient knowledge to support management representations that it has exercised reasonable diligence that (i) the unaudited interim financial statements do not contain any untrue statement of material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it is made, as of the date of, and for the periods presented by, the unaudited interim financial statements and (ii) the unaudited interim financial statements fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented by the unaudited interim financial

The Board of Directors is responsible for reviewing and approving the unaudited interim financial statements together with other financial information of the Company and for ensuring that management fulfills its financial reporting responsibilities. An Audit Committee assists the Board of Directors in fulfilling this responsibility. The Audit Committee meets with management to review the financial reporting process and the unaudited interim financial statements together with other financial information of the Company. The Audit Committee reports its findings to the Board of Directors for its consideration in approving the unaudited interim financial statements together with other financial information of the Company for issuance to the shareholders.

Management recognizes its responsibility for conducting the Company's affairs in compliance with established financial standards, and applicable laws and regulations, and for maintaining proper standards of conduct for its

IMMUNALL SCIENCE INC.
CONDENSED STATEMENTS OF FINANCIAL POSITION

(amounts in Canadian dollars)

(unaudited)

ASSETS

	Notes	March 31 2015	December 31 2014
CURRENT ASSETS			
Cash		-	\$ 1,698
Accounts receivable		-	-
GST receivable		1,483	1,408
Inventory		-	-
Prepaid expenses		396	396
		1,879	3,502
 PROPERTY, PLANT & EQUIPMENT			
	5		
		\$ 1,879	\$ 3,502

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable and accrued liabilities		\$ 83,605	\$ 83,683
		83,605	83,683

SHAREHOLDERS' EQUITY

Share capital	8	747,769	747,769
Contributed surplus		422,248	422,248
Retained Earnings (Deficit)		(1,251,743)	(1,250,198)
		(81,726)	(80,181)
		\$ 1,879	\$ 3,502

Approved on behalf of the Board

"M. Frank Phillet"
M. Frank Phillet
Director & C.O.O.

IMMUNALL SCIENCE INC.
CONDENSED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

(amounts in Canadian dollars)

(unaudited)

	Notes	Three months ended March 31	
		2015	2014
REVENUE			
COST OF SALES			
GROSS PROFIT			
EXPENSES			
Public company expenses		1,500	3,295
Office		45	70
Storage			149
Legal			2,393
Amortization			64
		<u>(1,545)</u>	<u>(5,971)</u>
NET LOSS		<u>\$ (1,545)</u>	<u>\$ (5,971)</u>
Basic and diluted loss per share		<u>\$ 0.000</u>	<u>\$ 0.000</u>

IMMUNALL SCIENCE INC.
CONDENSED STATEMENTS OF CASH FLOWS

(amounts in Canadian Dollars)

(unaudited)

	Notes	Three months ended March 31	
		2015	2014
OPERATING ACTIVITIES			
Loss from operations		\$ (1,545)	\$ (5,971)
Adjustments for:			
Amortization		-	64
Changes in non-cash working capital		(153)	2,900
Net cash provided by (used in) operating activities		<u>(1,698)</u>	<u>(3,007)</u>
Change in cash		(1,698)	(3,007)
Cash, beginning of period		<u>1,698</u>	<u>5,849</u>
Cash, end of period		<u><u>\$ -</u></u>	<u><u>\$ 2,842</u></u>

IMMUNALL SCIENCE INC.**CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY**

(amounts in Canadian Dollars)

(unaudited)

	Number of Notes common shares	Common shares at stated value	Contributed surplus	Deficit	Total Equity
Balance at December 31, 2013	33,435,762	\$ 747,769	\$ 422,248	\$ (1,174,975)	\$ (4,958)
Loss for the period				(5,971)	(5,971)
Balance at March 31, 2014	33,435,762	\$ 747,769	\$ 422,248	\$ (1,180,946)	\$ (10,929)
Balance at December 31, 2014	33,435,762	\$ 747,769	\$ 422,248	\$ (1,250,198)	\$ (80,181)
Loss for the period				(1,545)	(1,545)
Balance at March 31, 2015	33,435,762	\$ 747,769	\$ 422,248	\$ (1,251,743)	\$ (81,726)